Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Micro-RNA Expression Profiles in High Risk Prostate Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Wuerzburg University Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Universitaire Ziekenhuizen Leuven
Information provided by:
Wuerzburg University Hospital
ClinicalTrials.gov Identifier:
NCT01220427
First received: October 12, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted

October 12, 2010
October 12, 2010
June 2007
Not Provided
Recurrence free survival [ Time Frame: Yearly update until clinical progression ] [ Designated as safety issue: No ]
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.
Same as current
No Changes Posted
Cancer specific survival [ Time Frame: Yearly update until death ] [ Designated as safety issue: No ]
The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly until death.
Same as current
Not Provided
Not Provided
 
Micro-RNA Expression Profiles in High Risk Prostate Cancer
Micro-RNA Expression Profiles in High Risk Prostate Cancer

The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.

Not Provided
Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

University hospital, community hospital

  • Prostate Cancer
  • Radical Prostatectomy
Not Provided
Clinical high-risk prostate cancer, radical prostatectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
Not Provided
Not Provided

Inclusion Criteria:

Patients with clinically localised high risk prostate cancer (cT>2, bx GS >7, PSA >20 ng/ml) scheduled for radical prostatectomy.

Exclusion Criteria:

Non high risk prostate cancer

Male
35 Years to 80 Years
No
Contact: Martin H. Spahn, MD 0049931201 ext 32025 spahn_m@klinik.uni-wuerzburg.de
Germany
 
NCT01220427
mi-RNA HR-Pca
No
Martin Spahn, University Hospital Würzburg
Wuerzburg University Hospital
Universitaire Ziekenhuizen Leuven
Not Provided
Wuerzburg University Hospital
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP